 |
|
|
|
 |
|
|
|
| Article 1 to 10 out of 1350
|
|
-
Bone Medical further positive results from oral osteoporosis drug trial
(14 May 2008)
Bone Medical oral drug appears to match the injectable alternative
Bone Medical Limited has obtained important positive data on blood levels of peptide from testing its oral parathyroid hormone (PTH) CaPTHymone(TM) osteoporosis product. These results are from a second clinical trial of CaPTHymone(TM) conducted ......
-
NicOx announces initiation of first phase 1 study of investigational nitric oxide-donating agent in hypertensive patients
(14 May 2008)
NicOx S.A. announced that Merck & Co., Inc. has initiated the first in a series of planned clinical studies, in mild to moderate hypertensive patients, under the companies' collaborative agreement to develop new nitric oxide-donating ......
-
Affimed validates antibody target for cancer metastasis
(14 May 2008)
Affimed Therapeutics AG announced that a collaboration with Dr. Stefan Weiss at the Institute of Biochemistry of the Ludwig Maximilian University in Munich has strongly validated a target for cancer metastases amenable to the development of ......
-
FivePrime Reports Discovery of IL-34
(13 May 2008)
Science, researchers at Five Prime Therapeutics, Inc. report the discovery of Interleukin34, a novel cytokine, as well as the identification of an IL-34 receptor. "This work is a textbook example of how our platform enables us to make important ......
-
KeyNeurotek Pharmaceuticals Reports Positive Phase I Data of Its Cannabinoid Receptor-Agonist
(13 May 2008)
KeyNeurotek Pharmaceuticals AG announced positive results of a Phase I study with its cannabinoid receptor-agonist KN38-7271. KN38-7271 is being developed for the treatment of patients suffering from acute neurodegenerative incidents like a ......
-
DIREVO announces validation of bestMab
(08 May 2008)
New approach for the optimization of therapeutic antibodies generates optiMIRA, an enhanced version of Adalimumab (Humira)
DIREVO Biotech AG announced that it has validated its "bestMab(TM)" platform through the generation of an optimized version of the anti-inflammatory antibody, Adalimumab (HumiraŽ), with unprecedentedly strong binding properties. optiMIRA(TM) ......
-
Novartis Menveo vaccine shows superior immune response against four types of meningitis disease in pivotal phase III trial
(07 May 2008)
First Phase III, head-to-head data show Menveo may offer greater protection for adolescents compared to Menactra
New Phase III data for MenveoŽ (MenACWY-CRM) show that the vaccine produced a greater immune response against meningococcal serogroups A, C, W-135 and Y in adolescents 11-18 years of age compared to MenactraŽ. Infection with any of these four ......
-
Amylin Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
(07 May 2008)
Amylin Pharmaceuticals, Inc. announced the initiation of a Phase 2B clinical study evaluating various dosing combinations of pramlintide, an analog of the natural hormone amylin, and recombinant human leptin (r-metHuLeptin; metreleptin) for the ......
-
NicOx announces U.S. phase 2a results for PF-03187207 and gives an update on continuing NO-prostaglandin program
(07 May 2008)
NicOx S.A. announced the results of a U.S. phase 2 study, conducted by its partner Pfizer Inc, which compared the safety and efficacy of various doses of PF-03187207 to XalatanŽ (latanoprost) 0.005% in patients with primary open-angle glaucoma ......
-
Amorfix detects scrapie prions in blood from asymptomatic sheep
(05 May 2008)
Amorfix Life Sciences Ltd. announced the detection of endogenous prions in the blood plasma of asymptomatic scrapie infected sheep. The company had previously reported detecting symptomatic sheep which was a requirement for testing of human ......
|
|
|
Top